American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3

Overview

Journal Arthritis Rheumatol

Publisher Wiley

Specialty Rheumatology

Date 2021 Aug 4

PMID 34346564

Citations 79

Authors

Jeffrey R Curtis

Sindhu R Johnson

Donald D Anthony

Reuben J Arasaratnam

Lindsey R Baden

Anne R Bass

Cassandra Calabrese

Ellen M Gravallese

Rafael Harpaz

Andrew Kroger

Rebecca E Sadun

Amy S Turner

Eleanor Anderson Williams

Ted R Mikuls

Affiliations

Soon will be listed here.

Abstract

Objective: To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID-19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).

Methods: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.

Results: Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.

Conclusion: These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.

Citing Articles

Impact of the COVID-19 pandemic on the quality of care for juvenile idiopathic arthritis patients: insights from Thailand.

Pinpattanapong R, Sukharomana M, Charuvanij S Orphanet J Rare Dis. 2024; 19(1):320.

PMID: 39223582 PMC: 11367977. DOI: 10.1186/s13023-024-03330-7.

Community-engaged randomised controlled trial to disseminate COVID-19 vaccine-related information and increase uptake among Black individuals in two US cities with rheumatic conditions.

Sirek G, Erickson D, Muhammad L, Losina E, Chandler M, Son M BMJ Open. 2024; 14(8):e087918.

PMID: 39181556 PMC: 11344519. DOI: 10.1136/bmjopen-2024-087918.

Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting.

Torres-Rufas M, Vicente-Rabaneda E, Cardenoso L, Gutierrez A, Bong D, Valero-Martinez C Vaccines (Basel). 2024; 12(6).

PMID: 38932401 PMC: 11209506. DOI: 10.3390/vaccines12060672.

Risk of Recurrent Noninfectious Uveitis After Coronavirus Disease 2019 Vaccination in the United States.

Kumar A, Miller D, Sun Y, Arnold B, Acharya N Ophthalmol Sci. 2024; 4(4):100474.

PMID: 38827031 PMC: 11141252. DOI: 10.1016/j.xops.2024.100474.

COVID-19 Vaccine Effectiveness among Patients with Psoriatic Disease: A Population-Based Study.

Gazitt T, Eder L, Saliba W, Stein N, Feldhamer I, Cohen A Vaccines (Basel). 2024; 12(5).

PMID: 38793704 PMC: 11125670. DOI: 10.3390/vaccines12050453.

References

Perrot L, Hemon M, Busnel J, Muis-Pistor O, Picard C, Zandotti C . First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Lancet Rheumatol. 2021; 3(1):e6-e8. PMC: 7832430. DOI: 10.1016/S2665-9913(20)30396-9. View

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

Aikawa N, Campos L, Silva C, Carvalho J, Saad C, Trudes G . Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2011; 39(1):167-73. DOI: 10.3899/jrheum.110721. View

Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J . Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study. Rheumatology (Oxford). 2011; 51(4):695-700. DOI: 10.1093/rheumatology/ker389. View

Ribeiro A, Laurindo I, Guedes L, Saad C, Moraes J, Silva C . Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 65(3):476-80. DOI: 10.1002/acr.21838. View

Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L . Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020; 79(7):859-866. PMC: 7299648. DOI: 10.1136/annrheumdis-2020-217871. View

Rondaan C, Furer V, Heijstek M, Agmon-Levin N, Bijl M, Breedveld F . Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019; 5(2):e001035. PMC: 6744079. DOI: 10.1136/rmdopen-2019-001035. View

Oda R, Inagaki T, Ishikane M, Hotta M, Shimomura A, Sato M . Case of adult large vessel vasculitis after SARS-CoV-2 infection. Ann Rheum Dis. 2020; 82(1):e25. DOI: 10.1136/annrheumdis-2020-218440. View

Park J, Choi Y, Winthrop K, Song Y, Lee E . Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial. Ann Rheum Dis. 2019; 78(9):1283-1284. DOI: 10.1136/annrheumdis-2019-215187. View

10.

DSilva K, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace Z . COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol. 2020; 73(6):914-920. PMC: 8169514. DOI: 10.1002/art.41619. View

11.

Furer V, Rondaan C, Heijstek M, Agmon-Levin N, van Assen S, Bijl M . 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019; 79(1):39-52. DOI: 10.1136/annrheumdis-2019-215882. View

12.

Siegrist C, Ambrosioni J, Bel M, Combescure C, Hadaya K, Martin P . Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antivir Ther. 2012; 17(5):893-903. DOI: 10.3851/IMP2103. View

13.

Richi P, Martin M, de Ory F, Gutierrez-Larraya R, Casas I, Jimenez-Diaz A . Secukinumab does not impair the immunogenic response to the influenza vaccine in patients. RMD Open. 2019; 5(2):e001018. PMC: 6744077. DOI: 10.1136/rmdopen-2019-001018. View

14.

van der Maas A, Lie E, Christensen R, Choy E, de Man Y, van Riel P . Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis. 2012; 72(11):1800-5. DOI: 10.1136/annrheumdis-2012-202281. View

15.

Mikuls T, Johnson S, Fraenkel L, Arasaratnam R, Baden L, Bermas B . American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol. 2020; 73(2):e1-e12. DOI: 10.1002/art.41596. View

16.

Singh J, Furst D, Bharat A, Curtis J, Kavanaugh A, Kremer J . 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64(5):625-39. PMC: 4081542. DOI: 10.1002/acr.21641. View

17.

Ungaro R, Agrawal M, Park S, Hirten R, Colombel J, Twyman K . Autoimmune and Chronic Inflammatory Disease Patients with COVID-19. ACR Open Rheumatol. 2021; 3(2):111-115. PMC: 7882518. DOI: 10.1002/acr2.11221. View

18.

Mok C, Ho L, Fong L, To C . Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2012; 72(5):659-64. DOI: 10.1136/annrheumdis-2012-201393. View

19.

Hua C, Barnetche T, Combe B, Morel J . Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2013; 66(7):1016-26. DOI: 10.1002/acr.22246. View

20.

Topless R, Phipps-Green A, Leask M, Dalbeth N, Stamp L, Robinson P . Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. ACR Open Rheumatol. 2021; 3(5):333-340. PMC: 8126763. DOI: 10.1002/acr2.11252. View